Synthon Company Investment Thesis and Growth Strategy

Author

Reads 6.1K

Scientists in a Laboratory
Credit: pexels.com, Scientists in a Laboratory

Synthon's investment thesis is centered around developing and commercializing complex generic medicines.

The company focuses on bringing high-quality, affordable medicines to underserved markets.

Synthon's growth strategy involves expanding its product portfolio through strategic acquisitions and partnerships.

Goldman Sachs Deal

Goldman Sachs Asset Management agreed a more than €2bn deal to acquire Synthon from BC Partners.

BC Partners sold a majority stake in Synthon to Goldman Sachs Alternatives.

Under BC Partners’ active ownership, Synthon has expanded rapidly, more than doubling EBITDA.

The transaction maintains BC Partners’ momentum in realisations.

BC Partners will retain a minority stake in Synthon to support future growth.

Latham & Watkins advised BC Partners on the sale of a majority stake in Synthon.

The Latham team was led by London corporate partners Robbie McLaren and Maarten Overmars.

BC Partners Transactions

BC Partners acquired Synthon International Holding B.V. in 2019, a move that marked a significant milestone for the company.

Under BC Partners' active ownership, Synthon has expanded rapidly, more than doubling its EBITDA.

Credit: youtube.com, Synthon Blansko – Quality Control laboratories

BC Partners agreed to sell a majority stake in Synthon to Goldman Sachs Alternatives, a transaction that maintains BC Partners' momentum in realisations.

The private equity business at Goldman Sachs Alternatives acquired a majority stake in Synthon, a leading international pharmaceutical company, from funds advised by BC Partners.

BC Partners retained a minority stake in Synthon to support future growth.

Terms of the transaction were not disclosed.

Funding and Investors

Synthon has secured funding through a single round, a Grant (prize money) round on February 19, 2023, for $422K. This funding round was led by Gov.cz, a single investor.

The post-money valuation of Synthon after this funding round is $7,716,137.

Synthon's revenue multiple is 3,472,572.

Discover more: Round 2 (company)

Investment Thesis

As governments and healthcare systems seek to lower costs and drive savings, they're increasingly relying on the development of generic drugs. This sector growth is expected to be long-term, with many complex drugs being outsourced to specialists.

Synthon has multiple barriers-to-entry, including world-class R&D expertise, industry-leading IP capabilities, and high-quality manufacturing facilities. This provides a strong defensive moat against competition.

Credit: youtube.com, Investment Thesis

The company's lengthy development timelines (up to 5 years) and long-term exclusive contracts with renewal rates of over 99% offer downside-protected growth opportunities. This means investors can feel confident in the company's ability to deliver steady returns.

Synthon's high-calibre staff and facilities, strong reputation, and market-leading R&D/IP establish a long-term competitive advantage. This allows the company to capitalise on sector tailwinds and stay ahead of the competition.

The company's de-risked, long-term development pipeline offers strong revenue visibility and clear avenues for value creation through BC Partners' dedicated Portfolio Operations team. This provides a clear path for investors to see returns on their investment.

Here's an interesting read: Happy Returns (company)

News and Updates

Synthon has been recognized for its commitment to innovation and quality, earning a spot in the top 10 of the 2022 CPhI & P-MEC China Awards.

The company has a strong presence in the global market, with operations in over 40 countries across the Americas, Europe, and Asia.

Synthon's expertise in complex APIs and intermediates has made it a trusted partner for pharmaceutical companies around the world.

Synthon's partnership with the University of Groningen has led to the development of new APIs and intermediates, further solidifying its position in the industry.

Value Chain and Operations

Credit: youtube.com, How Synthon Builds Powerful Partnerships Between Supply Chain and IT Teams

Synthon's value chain is a key aspect of its success as a specialty pharmaceutical company. It has a strong presence in research and development, production, and regulatory affairs.

The company has over 1,250 employees across 9 countries, demonstrating its global reach and capabilities.

Synthon aims to provide an integrated solution for its partners through its value chain, offering a comprehensive approach to pharmaceutical development and production.

Patents

Synthon has filed a total of 58 patents, covering a range of topics.

The company's patent portfolio includes inventions related to antineoplastic drugs, estranes, and experimental cancer drugs.

Synthon's patents have been granted for specific processes, such as the process for making palbociclib.

The patent for the process of making palbociclib was granted on March 4, 2025, after being filed on September 26, 2023.

Synthon's patents often have multiple related topics, such as protein kinase inhibitors, lactams, and estranes.

Here are the top 3 patent topics for Synthon:

  • Antineoplastic drugs
  • Estranes
  • Experimental cancer drugs

Value Chain of a Specialty Pharma Company

Credit: youtube.com, Mapping the Optimal Supply Chain for Biologics, from Formulation to Clinic

A specialty pharmaceutical company's value chain is a crucial aspect of its operations. Synthon, a company with over 1,250 employees across 9 countries, has a robust value chain that enables it to develop and produce high-quality products.

Synthon has expanded globally through acquisitions and new offices, demonstrating its ability to scale its value chain.

The company's value chain includes research and development, production, and regulatory affairs. Synthon aims to climb the pharmaceutical ladder by developing life cycle products, biosimilars, and new biological entities using its expertise in these areas.

Synthon provides an integrated solution for partners through its value chain. It seeks emerging market growth and focus in therapeutic areas, showcasing its commitment to expanding its value chain.

Frequently Asked Questions

Who is the manufacturer of Synthon?

Synthon is a Dutch multinational company that produces generic human drugs. It was founded by Jacques Lemmens and Marijn Oosterbaan, two organic chemists, in 1991.

Who owns synthon?

Synthon is majority-owned by Goldman Sachs Alternatives, with BC Partners retaining a minority stake. This partnership supports Synthon's continued growth and performance.

What does synthon do?

Synthon develops, manufactures, and sells complex generic pharmaceuticals worldwide. They specialize in creating high-quality, affordable medicines for global markets.

Where is Synthon Pharma headquarters?

Our headquarters is located in Nijmegen, the Netherlands. We are centrally managed from our global headquarters there.

Lynette Kessler

Lead Writer

Lynette Kessler is a seasoned writer with a keen eye for detail and a passion for creating informative content. With a focus on business and finance, she has established herself as a trusted voice in the industry. Her expertise spans a range of topics, from product liability insurance to business insurance costs.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.